Multiple Sclerosis
Neurofilament light chain predicted confirmed disability worsening at 1 to 2 years in MS
For those with multiple sclerosis, presence of elevated neurofilament light chain biomarkers was associated with symptom progression that predicted clinical disease worsening within 1 to 2 years, according to research from JAMA Neurology.
$10M research initiative will fund research on neuroinflammation
The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.
Ace the Case: A 52-Year-Old Woman With Gradual Walking Difficulties
There is no commercial support for this activity.
Immersive virtual reality reduces cancer-related pain, distress
Virtual reality interventions can serve as acceptable treatments with the potential to improve both physical and psychological consequences of certain long-term illnesses, according to a study published in BMJ Supportive & Palliative Care.
Twice-daily evobrutinib linked to lower relapse, less clinical worsening after 5 years
Treatment with evobrutinib in continuous, twice-daily dosing provided the lowest relapse rate and highest arrest of clinical worsening after 5 years in those with relapsing multiple sclerosis, according to data presented at ECTRIMS 2023.
Ublituximab reduced brain volume loss by 22%, suppressed new lesion formation
Treatment with ublituximab suppressed new lesion formations after 1 year while reducing thalamic volume loss and increasing T1 hypointense lesion volume compared with teriflunomide, according to data presented at ECTRIMS 2023.
Frexalimab linked to reduction in lesion activity, well tolerated in relapsing MS
In a cohort of individuals with relapsing multiple sclerosis, treatment with frexalimab significantly reduced new MRI lesions by week 24, according to a data presented at ECTRIMS 2023.
Ozanimod treatment linked to functional, cognitive improvements, reduced lesions in MS
Following 1 year of treatment with ozanimod, individuals with relapsing forms of multiple sclerosis saw functional and cognitive improvements as well as a reduction in MRI lesions, according to interim data presented at ECTRIMS 2023.
Relapse, disease worsening similar with ozanimod treatment in relapsing MS
Those with relapsing forms of multiple sclerosis treated with ozanimod saw relapse-associated worsening and progression-independent relapse activity contributed similarly to disability progression, according to research from ECTRIMS 2023.
Fenebrutinib linked to reduced lesion activity, higher CSF penetration in MS at 12 weeks
In relapsing forms of multiple sclerosis, fenebrutinib treatment led to reduction of lesion activity and resulted in higher penetration into cerebrospinal fluid at 12 weeks, according to research from ECTRIMS 2023.